Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna is using OpenAI's ChatGPT and other tools extensively. In particular, OpenAI's solution is helping with some much-dreaded work.

Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?

Moderna (MRNA) shares lost ground in intraday trading Friday as the biotech's effort to move beyond just a COVID-19 vaccine was stalled somewhat by U.S. regulators looking at its new shot to treat respiratory syncytial virus (RSV).

Moderna Stock Slips as FDA Delays RSV Vaccine Approval

Moderna stock skidded Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine

Moderna Inc.'s stock fell 1.8% early Friday, after the company said the Food and Drug Administration will not complete its review of the company's respiratory syncytial virus, or RSV, vaccine by the original deadline of May 12.

Moderna says FDA will not complete review of RSV vaccine by May 12 deadline

iShares Nasdaq Biotechnology ETF

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).

Will the Biotech Sector Shift From Lagger to Leader?

The U.S. Food and Drug Administration has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some "administrative constraints", the company said on Friday.

US FDA pushes decision on Moderna's RSV vaccine to end of this month

The FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said.

Moderna says FDA delayed RSV vaccine approval to end of May

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024 Agency has indicated it expects to complete the review by end of May CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna's investigational respiratory syncytial virus (RSV) vaccine, by the previously communicated Prescription Drug User Fee Act (PDUFA) date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024.

Moderna Announces Update on Investigational RSV Vaccine

Prior to the COVID pandemic, the biopharma outfit wasn't a particularly well-known name. Being one of the few pharma companies that could quickly come up with a vaccine, however, catapulted its stock.

If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today

Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?

Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?

Exelixis

Intellia Therapeutics

From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select Industry Index has dropped by 4%.

Just Say No to Drugs: 3 Pharma Stocks to Avoid

Disney

Peloton

Verizon

Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.

Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.

Moderna's earnings per share exceeded analyst predictions but were still well down from 2023's Q1. Revenue for Q1 showcased significant outperformance compared to analysts' forecasts.

Moderna's Loss in Q1 Was Less Than Expected

Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.

Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar

Investors and analysts broadly expected the biotech's results to wither in the first quarter, and they were right. Still, it did better than many anticipated.

Why Moderna Stock Blasted 13% Higher Today

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

Novo Nordisk

Here are two biotech stocks to watch after their recent earnings report.

2 Biotech Stocks To Watch Today Amid Earnings

Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago.

Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates

Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year. Moderna beats loss estimates, revenue expectations In the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.

Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch

Apple

AMC Entertainment

Advanced Micro Devices

Amazon

Chipotle

ConocoPhillips

Carvana

eBay

Etsy

VanEck Vectors Gold Miners ETF

GameStop

Intuitive Surgical

McDonald's

Microsoft

NVIDIA

Pinterest

QUALCOMM

Starbucks

Super Micro Computer

Snap

Spotify

Stanley Black & Decker

Large-cap growth funds have been in the sweet spot for a few years now, thanks to megacap tech holdings.

Highly ranked manager who bet on Mag 7 giants looks to these second-order winners from AI

The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.

Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold

Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.

Moderna quarterly sales beat expectations but plummet from previous year

Moderna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine maker looks to launch its second product in the U.S. later this year.

Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch

Moderna beat first-quarter expectations Thursday. The news could bolster Moderna stock which is approaching its first breakout in over a year.

Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?

Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma Advanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor event CAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2024. "As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are exercising financial discipline and have intensified our focus on building and utilizing AI technologies to further streamline operations and enhance productivity," said Stéphane Bancel, Chief Executive Officer of Moderna.

News for Moderna Stock (MRNA)